GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

acoltremon   Click here for help

GtoPdb Ligand ID: 4343

Synonyms: AR-15512 | AR15512 | AVX-012 | Tryptyr® | WS 12 | WS-12
Approved drug PDB Ligand
acoltremon is an approved drug
Compound class: Synthetic organic
Comment: Acoltremon (AR-15512) is a transient receptor potential melastatin 8 (TRPM8) agonist [1-3]. Topical application of TRPM8 agonists was proposed to relieve ocular pain and discomfort in dry eye disease [5-6], via stimulation of tear production through opening of TRPM8 calcium channels expressed in branches of the trigeminal nerve that innervate the cornea and eye lids. It also produces menthol-like cooling effects.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 38.33
Molecular weight 289.2
XLogP 5.2
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(cc1)NC(=O)C1CC(C)CCC1C(C)C
Isomeric SMILES COc1ccc(cc1)NC(=O)[C@@H]1C[C@H](C)CC[C@H]1C(C)C
InChI InChI=1S/C18H27NO2/c1-12(2)16-10-5-13(3)11-17(16)18(20)19-14-6-8-15(21-4)9-7-14/h6-9,12-13,16-17H,5,10-11H2,1-4H3,(H,19,20)/t13-,16+,17-/m1/s1
InChI Key HNSGVPAAXJJOPQ-XOKHGSTOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Ma S, G G, Ak VE, Jf D, H H. (2008)
Menthol derivative WS-12 selectively activates transient receptor potential melastatin-8 (TRPM8) ion channels.
Pak J Pharm Sci, 21 (4): 370-8. [PMID:18930858]
2. Rodríguez-Arévalo S, Pujol E, Abás S, Galdeano C, Escolano C, Vázquez S. (2021)
Synthesis, Characterization and HPLC Analysis of the (1S,2S,5R)-Diastereomer and the Enantiomer of the Clinical Candidate AR-15512.
Molecules, 26 (4). [PMID:33572112]
3. Sherkheli MA, Vogt-Eisele AK, Bura D, Beltrán Márques LR, Gisselmann G, Hatt H. (2010)
Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship.
J Pharm Pharm Sci, 13 (2): 242-53. [PMID:20816009]
4. Wirta DL, Senchyna M, Lewis AE, Evans DG, McLaurin EB, Ousler GW, Hollander DA. (2022)
A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1).
Ocul Surf, 26: 166-173. [PMID:35970431]
5. Yang JM, Li F, Liu Q, Rüedi M, Wei ET, Lentsman M, Lee HS, Choi W, Kim SJ, Yoon KC. (2017)
A novel TRPM8 agonist relieves dry eye discomfort.
BMC Ophthalmol, 17 (1): 101. [PMID:28651550]
6. Yoon HJ, Kim J, Yang JM, Wei ET, Kim SJ, Yoon KC. (2021)
Topical TRPM8 Agonist for Relieving Neuropathic Ocular Pain in Patients with Dry Eye: A Pilot Study.
J Clin Med, 10 (2). [PMID:33445485]